Avicanna Files Patent For New Cannabinoid-Based Epilepsy Medication

Avicanna Inc., (TSX: AVCN) (OTCQX: AVCNF) a biopharmaceutical company focused on cannabinoid-based medicines, has filed a provisional patent application that aims to patent the use of a novel cannabinoid formulation for reducing or eliminating seizures and sudden death in epilepsy.

Encompassed in the company’s approach to develop, manufacture and commercialize plant-derived, cannabinoid-based pharmaceuticals is the that led to this patent application.

The findings originated from a collaboration with researcher Dr. Peter Carlen at the University Health Network in Canada.

In preclinical …

Full story available on Benzinga.com

More Avicanna Files Patent For New Cannabinoid-Based Epilepsy Medication